About this trial
The HyperLa study investigates whether a person's "glycolyticness"-the efficiency with which their body uses glycolysis for energy-can predict how much their muscles will grow (hypertrophy) in response to resistance training. Participants will undergo a specialized "vLapeak" test, which measures the maximal rate of lactate accumulation during a 10-second all-out cycling sprint, to determine their individual glycolytic power. Following this initial assessment, participants will complete eight weeks of standardized, twice-weekly resistance training focused on the lower body. The study aims to determine if individuals with higher initial vLapeak values experience greater increases in muscle size compared to those with lower values. This research may help explain why people respond differently to exercise and support the development of personalized training programs.
Eligibility criteria
Qualifiers
Body Mass Index (BMI) between 20-29 kg/m2
No structured resistance training performed in the last twelve months.
Maximum of four sessions per week of recreational or low-to-moderate aerobic endurance activity.
No history of competitive strength or physique sports.
Disqualifiers
Diagnosed cardiovascular, pulmonary, metabolic, neuromuscular, or orthopaedic disease that contraindicates exercise.
Positive response to any question on the PAR-Q 2025 questionnaire.
Current use of anabolic steroids, creatine, or other substances known to strongly influence muscle hypertrophy.
Regular engagement in shift work.
Trial design
Treatments tested in this trial
- Hypertrophy-focused Resistance Training
Treatment groups
Sponsors and collaborators
Technical University of Munich
Lead sponsor
Chemnitz University of Technology
Collaborator
DLR German Aerospace Center
Collaborator
University of Jyvaskyla
Collaborator
University of Limerick
Collaborator
IST University of Applied Sciences Düsseldorf
Collaborator
Institute for Applied Training Science (IAT/FES e.V.)
Collaborator